Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PACB 
Pacific Biosciences of California (PACB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: PACB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $2.03
Year Target Price $2.03
| 5 | Strong Buy |
| 1 | Buy |
| 8 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.64% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 387.11M USD | Price to earnings Ratio - | 1Y Target Price 2.06 |
Price to earnings Ratio - | 1Y Target Price 2.06 | ||
Volume (30-day avg) - | Beta 2.1 | 52 Weeks Range 0.85 - 2.72 | Updated Date 06/29/2025 |
52 Weeks Range 0.85 - 2.72 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.74 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1164.47% |
Management Effectiveness
Return on Assets (TTM) -31.7% | Return on Equity (TTM) -177.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 744610667 | Price to Sales(TTM) 2.54 |
Enterprise Value 744610667 | Price to Sales(TTM) 2.54 | ||
Enterprise Value to Revenue 4.89 | Enterprise Value to EBITDA -4.15 | Shares Outstanding 300084992 | Shares Floating 297885064 |
Shares Outstanding 300084992 | Shares Floating 297885064 | ||
Percent Insiders 9.06 | Percent Institutions 66.11 |
Analyst Ratings
Rating 3.79 | Target Price 2.03 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 8 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Pacific Biosciences of California
Company Overview
History and Background
Pacific Biosciences of California, Inc. (PacBio) was founded in 2004. The company is known for its Single Molecule, Real-Time (SMRT) sequencing technology. Significant milestones include the development of the PacBio RS system, subsequent advancements in sequencing chemistry and instrumentation, and expansion into new applications such as human genetics and plant and animal sciences.
Core Business Areas
- Sequencing Systems: Development, manufacturing, and commercialization of sequencing systems based on SMRT technology, including the Revio and Sequel IIe instruments.
- Consumables: Manufacturing and sale of consumables required for PacBio sequencing systems, such as SMRT cells and reagents.
- Services: Provides support services, training, and instrument maintenance.
Leadership and Structure
Christian Henry is the President and CEO. The company has a typical corporate structure with departments for research and development, manufacturing, sales, marketing, and operations. They have a board of directors that helps govern the organization
Top Products and Market Share
Key Offerings
- Revio: High-throughput long-read sequencing system, offering increased scale and reduced cost. Competing technologies are short read sequencing from Illumina and other long read technologies from Oxford Nanopore. Estimated market share data unavailable, but a strategic product. It will allow the company to compete more heavily in large scale whole genome sequencing projects.
- Sequel IIe: PacBio's previous generation long-read sequencing platform that provides highly accurate long reads. Competitors include Illumina and Oxford Nanopore. Estimated market share data unavailable, but the Sequel IIe is an important source of revenue.
- SMRTbell Prep Kits: Kits to prepare DNA for sequencing on PacBio instruments. Competitors include Illumina, Oxford Nanopore and a host of library preparation kit manufacturers. Estimated market share data unavailable.
Market Dynamics
Industry Overview
The genomics industry is experiencing rapid growth, driven by increasing demand for DNA sequencing in research, clinical diagnostics, and drug discovery. Key trends include the increasing adoption of long-read sequencing, the development of new sequencing technologies, and the growing importance of bioinformatics and data analysis.
Positioning
PacBio is positioned as a leader in long-read sequencing, focusing on providing highly accurate long reads for applications such as *de novo* genome assembly, structural variant detection, and epigenetic studies. Its competitive advantages include its SMRT technology, high accuracy, and long read lengths.
Total Addressable Market (TAM)
The estimated TAM for long-read sequencing is several billion USD. PacBio is positioned to capture a significant portion of this market through continued innovation and expansion of its product offerings.
Upturn SWOT Analysis
Strengths
- High accuracy long reads
- SMRT technology
- Established presence in long-read sequencing market
- Strong brand recognition
- Revio platform increasing throughput and decreasing cost
Weaknesses
- Higher instrument and consumables costs compared to short-read sequencing
- Slower throughput compared to some short-read sequencing platforms
- Requires specialized expertise for data analysis
- Company has not yet reached profitability
- Limited Market Share as compared to competitors
Opportunities
- Growing demand for long-read sequencing in various applications
- Development of new sequencing technologies
- Expansion into new markets, such as clinical diagnostics
- Strategic partnerships and collaborations
- Further reduction in sequencing costs
Threats
- Competition from established sequencing companies, like Illumina
- Emergence of new sequencing technologies
- Price pressure in the sequencing market
- Economic downturn impacting research funding
- Regulatory hurdles in clinical diagnostics
Competitors and Market Share
Key Competitors
- ILMN
- ONT.L
Competitive Landscape
PacBio's advantage lies in long-read accuracy, while Illumina dominates the overall sequencing market due to its cost effectiveness and wide range of applications. Oxford Nanopore offers long reads with faster turnaround but with a trade-off in accuracy as compared to PacBio.
Major Acquisitions
Omniome
- Year: 2022
- Acquisition Price (USD millions): 800
- Strategic Rationale: Expand its sequencing technology portfolio and develop short-read sequencing capabilities. It later abandoned the Omniome technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth unavailable at time of generation, requiring live data access. Likely to show strong growth in revenue due to increasing adoption of long-read sequencing.
Future Projections: Future Projections unavailable at time of generation, requiring live data access. Analyst estimates typically project continued revenue growth, driven by the Revio system and expansion into new markets.
Recent Initiatives: Recent initiatives include the launch of the Revio sequencing system, collaborations with pharmaceutical companies, and expansion of its product portfolio.
Summary
PacBio is a leader in long-read sequencing, boasting accurate technology and growing market presence. The Revio system enhances throughput and reduces costs, but high expenses and limited throughput remain weaknesses. Growth opportunities include expanding applications and partnerships, but competition from Illumina and emerging technologies pose threats. Overall, PacBio shows promise but faces challenges in the competitive genomics market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Industry Reports
- Analyst Estimates
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Financial data and future projections are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pacific Biosciences of California
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2010-10-27 | President, CEO & Director Mr. Christian O. Henry M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 575 | Website https://www.pacb.com |
Full time employees 575 | Website https://www.pacb.com | ||
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.